Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.

Annals of hematology·2026

Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026

Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026

Same author

Therapy-driven clonal dynamics in chronic lymphocytic leukemia.

Seminars in cancer biology·2026

Same author

The deubiquitinase activity of CYLD is required for B cell differentiation.

Cell death & disease·2026

Same author

Longitudinal profiling of antigen receptor gene repertoire dynamics in kidney transplant recipients after multiple SARS-CoV-2 vaccinations.

ImmunoHorizons·2026

Search research articles

Related Experiment Video

Updated: Oct 15, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Precision diagnostics in lymphomas - Recent developments and future directions.

Larry Mansouri¹, Birna Thorvaldsdottir¹, Stamatia Laidou²

¹Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Seminars in Cancer Biology

|October 26, 2021

Summary

Genomic analysis reveals diverse genetic mutations in lymphomas, aiding diagnosis and prognosis. Future comprehensive sequencing may enable precision medicine for tailored lymphoma treatments.

Keywords:

Lymphoma Precision diagnostics Precision medicine Prognostication Therapy prediction

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Related Experiment Videos

Last Updated: Oct 15, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

Area of Science:

Hematology
Oncology
Genetics

Background:

Genetics is crucial for lymphoma subclassification and risk stratification.
High-throughput sequencing has detailed the genomic landscape of major lymphoma types.
Lymphoma genetics reflect significant clinical heterogeneity.

Purpose of the Study:

To review clinically relevant diagnostic, prognostic, and predictive genetic markers in lymphomas.
To discuss the role of comprehensive genomic characterization in precision diagnostics.
To explore the potential for tailored precision therapy in lymphomas.

Main Methods:

Review of current literature on lymphoma genetics.
Analysis of high-throughput sequencing data in lymphoma studies.
Discussion of diagnostic and prognostic genetic markers.

Main Results:

Lymphoma genetic landscapes are diverse, with some entities having predominant mutations and others many recurrent mutations.
Genomic studies have improved understanding of lymphoma evolution and identified new diagnostic/prognostic markers.
Limited gene mutations currently predict treatment response.

Conclusions:

Comprehensive genomic characterization is essential for advancing lymphoma diagnostics.
Precision diagnostics in lymphomas can lead to tailored precision therapy.
Further research into predictive genetic markers is needed for personalized treatment selection.